Literature DB >> 4368383

Adriamycin in advanced bronchogenic carcinoma.

E P Cortes, H Takita, J F Holland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4368383     DOI： 10.1002/1097-0142(197409)34:3<518::aid-cncr2820340307>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  3 in total

1.  Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.

Authors:  Toshiyuki Sawa; Takashi Yana; Minoru Takada; Takahiko Sugiura; Shinzoh Kudoh; Tadashi Kamei; Takeshi Isobe; Hidehiko Yamamoto; Soichiro Yokota; Nobuyuki Katakami; Yuji Tohda; Akira Kawakami; Yoichi Nakanishi; Yutaka Ariyoshi
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

2.  Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.

Authors:  Koji Takeda; Nobuhide Takifuji; Shunichi Negoro; Kiyoyuki Furuse; Shinichiro Nakamura; Yoshiki Takada; Takanobu Hoso; Shinichi Hayasaka; Takashi Nakano; Jun Araki; Hiroshi Senba; Fumiyuki Iwami; Yasufumi Yamaji; Masahiro Fukuoka; Harumichi Ikegami
Journal:  Invest New Drugs       Date:  2007-03-10       Impact factor: 3.850

Review 3.  Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; M Clerici; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.